[1]陈毅然,张文富.基于分段论治理论治疗肝硬化腹水研究进展[J].陕西中医,2023,(10):1487-1490.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.035]
　CHEN Yiran,ZHANG Wenfu.Research progress on the treatment of cirrhotic ascites based on the theory of segmented treatment[J].,2023,(10):1487-1490.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.035]
点击复制

基于分段论治理论治疗肝硬化腹水研究进展
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年10期
页码:
1487-1490
栏目:
综 述
出版日期:
2023-10-05

文章信息/Info

Title:
Research progress on the treatment of cirrhotic ascites based on the theory of segmented treatment
作者:
陈毅然1; 张文富2
(1.广西中医药大学,广西 南宁 530200; 2.广西中医药大学第一附属医院,广西 南宁 530023)
Author(s):
CHEN Yiran; ZHANG Wenfu
(Guangxi University of Traditional Chinese Medicine,Nanning 530200,China)
关键词:
肝硬化腹水;  臌胀;  三线治疗;  分段论治;  疏肝
Keywords:
Liver cirrhosis ascites;  Tympanites;  Three-line treatment mode;  Segmented theory;  Soothing the liver
分类号:
R 657.31
DOI:
DOI:10.3969/j.issn.1000-7369.2023.10.035
文献标志码:
A
摘要:
肝硬化腹水归属中医学“臌胀”范畴,是临床上常见难治性并发症,目前临床医学根据腹水及伴随并发症的严重程度,治疗主张采用三线治疗模式,一线以药物治疗手段为主,二线以药物配合穿刺置管引流,三线以体外器械辅助为主,总体覆盖疾病发展的全过程。中医治疗以整体观念为基础,以辨证论治为原则,认为臌胀发病涉及肝脾肾三脏,准确把握气、血、水在不同阶段的关系,提出治早宜疏肝、中宜利肠胃、晚宜扶正补虚的分段施治原则。肝硬化腹水患者病情易反复,易发生感染、肝肾功能衰竭、电解质紊乱等严重并发症,预后情况较差,且临床长期使用利尿剂、血管活性药物、穿刺引流术配合白蛋白输注等手段疗效有限。因此如何降低腹水的复发率,减少并发症的产生,提高患者生活质量是目前临床研究的热门领域。临床医学三线疗法与中医分段施治有相似之处,现通过整理近5年中西医基于分段论治疗该疾病的研究进展,进一步探讨中西医协同治疗的优势。
Abstract:
Cirrhotic ascites belongs to the category of “tympanites” in traditional Chinese medicine.At present,according to the severity of ascites and accompanying complications,clinical medicine advocates the use of a three-line treatment mode.First,the scheme is mainly based on drug treatment; second,it is combined with puncture and catheter drainage; and the last scheme is mainly assisted by external instruments.The above three scenarios generally cover the whole process of disease development.The treatment of traditional Chinese medicine is based on the holistic concept and the principle of syndrome differentiation and treatment.It is believed that the incidence of tympanites involves the three organs of the liver,spleen,and kidney.It is necessary to accurately grasp the relationship between qi,blood,and water at different stages and put forward the principle of staged treatment by soothing the liver in the early stage,benefiting the intestine and stomach in the middle stage,and strengthening the body's resistance and tonifying deficiency in the late stage.Patients with cirrhotic ascites are prone to relapse and are prone to serious complications such as infection,liver and kidney failure,and electrolyte disorders,for which the prognosis is poor,and the long-term use of diuretics,vasoactive drugs,puncture,and drainage combined with albumin infusion has limited efficacy.Therefore,how to reduce the recurrence rate of ascites,reduce the occurrence of complications,and improve the quality of life of patients is a hot field of clinical research.There are similarities between the three-line therapy of clinical medicine and the segmented treatment of traditional Chinese medicine.By sorting out the research on the integrative medicine treatment for the disease based on the segmentation theory in the past five years,the advantages of integrated medicine are further discussed.

参考文献/References:

[1] Rouviere CP,Dousson CB,Tavis JE.HBV replication inhibitors[J].Antiviral Research,2020,179:104815.
[2] Muhammad SF,Tavankit S,Hina A,et al.A guide to diagnosing and managing ascites in cirrhosis[J].The Journal of Family Practice,2021,70(4):174-181.
[3] 廖 娟,王建超,玉 叶,等.肝硬化门脉高压的病理生理机制[J].辽宁中医杂志,2020,47(6):71-75.
[4] 张继红,李素领,冯蕾心,等.基于肠-肝轴探讨肝性脑病的中西医发病机制[J].中医学报,2022,37(9):1877-1883.
[5] Gedgaudas R,Bajaj JS,Skieceviciene J,et al.Circulating microbiome in patients with portal hypertension[J].Gut Microbes,2022,14(1):2029674.
[6] 徐小元,丁惠国,李文刚,等.肝硬化腹水及相关并发症的诊疗指南(2017,北京)[J].中华胃肠内镜电子杂志,2018,5(1):1-17.
[7] 董晓辉,曾 星,侯跃钢,等.恩替卡韦对HBeAg阳性慢性乙型病毒性肝炎患者血清YKL-40、CEA水平的影响[J].黑龙江医药科学,2022,45(1):42-43.
[8] 刘小莹,郑宏波,王山军,等.恩替卡韦单药方案维持对初始行拉米夫定+阿德福韦酯方案治疗慢性乙型肝炎及慢性乙型肝炎后肝硬化疗效影响[J].陕西医学杂志,2020,49(4):502-505.
[9] 潘 琳.观察托伐普坦治疗慢性心力衰竭合并低钠血症患者的近期疗效及安全性[J].中国医药指南,2021,19(30):95-97.
[10] 雷 鸣.托伐普坦与常规利尿剂治疗肝硬化腹水伴低钠血症的疗效及安全性对比分析[J].中国现代药物应用,2021,15(17):211-214.
[11] 中华医学会消化病学分会肝胆疾病学组,中国研究型医院学会肝病专业委员会.特利加压素在肝硬化并发症临床应用的实践指导(2021版)[J].中华肝脏病杂志,2022,30(8):859-865.
[12] 钟平玉,苏雪梅,林 栋.特利加压素联合人血白蛋白治疗肝硬化顽固性腹水的临床效果观察[J].基层医学论坛,2021,25(25):3646-3648.
[13] Bettinger D,Thimme R,Schulthei M.Implantation of transjugular intrahepatic portosystemic shunt(TIPS):Indication and patient selection[J].Current Opinion in Gastroenterology,2022,38(3):221-229.
[14] 司 毅,薛 挥,靳伟民.TIPS与EVL预防肝硬化静脉曲张再出血临床疗效对比研究[J].陕西医学杂志,2018,47(2):159-161.
[15] 周翔天,夏粤华,李 旭,等.三种不同技术治疗老年顽固性肝硬化腹水效果对比[J].中国老年学杂志,2022,42(7):1626-1629.
[16] 王本贤,李 伟,李东生,等.腹水浓缩回输联合抗感染治疗失代偿期乙型肝炎肝硬化患者疗效研究[J].实用肝脏病杂志,2022,25(2):247-250.
[17] 付 琳.《黄帝内经》诸湿肿满皆属于脾理论临床验案举隅[J].光明中医,2022,37(22):4153-4155.
[18] 潘源乐,刘妙华,刘馥春,等.旴江医家龚廷贤辨治臌胀思想探究[J].江西中医药,2020,51(12):3-4,18.
[19] 杨 兰,钟 森.朱丹溪治疗鼓胀八法[J].世界最新医学信息文摘,2019,19(96):262-266.
[20] 段晓娟,邓 春,王欢黎,等.陈文慧分期论治肝硬化腹水经验[J].中医药通报,2022,21(3):19-21.
[21] 唐颖慧,李粉萍,薛敬东,等.张氏肝病流派从“补肝体强肝用”辨治臌胀[J].陕西中医,2022,43(6):763-766.
[22] 杨 佼,陈兰羽,吕文良.中医“三阶疗法”治疗肝硬化腹水体会[J].中国中医急症,2012,21(11):1795-1796.
[23] 赵 丹,徐建良,杨 妮,等.海珠益肝加减方治疗肝硬化腹水临床观察[J].现代中西医结合杂志,2022,31(7):909-913.
[24] 张云城,盛国光,胡世平.海珠益肝加味方对刀豆蛋白A诱导免疫性肝损伤小鼠的保护作用[J].世界中医药,2020,15(9):1296-1299.
[25] 沈 峰,王秀玲,齐 艳.白牵牛散穴位贴敷联合西药治疗乙型肝炎肝硬化腹水的研究[J].中西医结合肝病杂志,2020,30(4):300-302,317.
[26] 赵莉萍,陈 慧,李春平,等.子午流注巳时穴位贴敷在肝硬化腹水患者护理中的应用[J].福建中医药,2022,53(7):61-63.
[27] 宋晓丹.雷火灸联合中西医结合药物治疗乙型肝炎肝硬化腹水的临床研究[J].中西医结合研究,2019,11(2):69-73.
[28] 蒋 鑫,姜 莹,李秀云.椒目泄水贴穴位外敷联合西药治疗肝硬化腹水30例临床观察[J].湖南中医杂志,2021,37(9):74-77.
[29] 谢 蓉,蔡翠珠,王月平.护肝利水汤联合中药敷脐对肝硬化腹水患者门静脉压力的影响[J].湖北中医药大学学报,2022,24(5):32-35.
[30] 高 玲,李 嘉,陈珊珊,等.马兰草脐灸结合健脾活血祛湿方治疗肝硬化腹水的临床疗效[J].中国临床研究,2020,33(2):158-162.
[31] 王 岗,朱 琦,陈 新,等.利水消臌膏联合肝病治疗仪治疗乙肝肝硬化顽固性腹水的临床疗效[J].中国实验方剂学杂志,2022,28(22):123-130.
[32] 卢慧民.中西药合用治疗肝硬化腹水临床观察[J].实用中医药杂志,2022,38(8):1349-1351.
[33] 梁浩卫,刘全忠.补肾益肝方治疗50例肝硬化腹水患者的临床观察[J].世界中西医结合杂志,2022,17(5):1009-1012.
[34] 石 磊,郝建梅,杭嘉敏,等.甲苓饮加减治疗气阴两虚型肝硬化腹水的效果及对患者血清相关炎性细胞因子水平的影响[J].海南医学,2021,32(11):1405-1408.
[35] 马娟娟,刘亚珠.养阴利水方配合放腹水输注白蛋白治疗肝硬化顽固性腹水临床研究[J].陕西中医,2021,42(1):87-89.
[36] 段成颖.附子理中汤合五苓散加减辅治肝硬化腹水脾肾阳虚型临床观察[J].实用中医药杂志,2022,38(2):276-278.
[37] 李 学,邸贺骞,王玉虎,等.消臌软坚丸联合脾肾阳亏胶囊治疗脾肾阳虚型肝硬化腹水疗效观察[J].西藏医药,2021,42(4):142-144.
[38] 张译文,卢秉久.实脾饮治疗肝硬化腹水的作用机制研究[J].中医临床研究,2022,14(26):43-46.

相似文献/References:

[1]杨广栋,高志远,李卫民,等.益气活血利水贴敷脐治疗肝硬化腹水疗效及对患者生存质量研究*[J].陕西中医,2019,(11):1503.
　YANG Guangdong,GAO Zhiyuan,LI Weimin,et al.The clinical efficacy and quality of life evaluation of Yiqi Huoxue Lishui stick in treating ascites due to cirrhosis[J].,2019,(10):1503.
[2]张会涛,尚 丽,李秋雅,等.护肝利水汤联合特利加压素治疗肝硬化腹水临床疗效及对患者血清学指标与门静脉压力的影响*[J].陕西中医,2020,(5):593.[doi:DOI:10.3969/j.issn.10007369.2020.05.011]
　ZHANG Huitao,SHANG Li,LI Qiuya,et al.Effects of Hugan Lishui decoction combined with terlipressin on clinical efficacy,serum index and portal venous pressure in patients with liver cirrhosis and ascites[J].,2020,(10):593.[doi:DOI:10.3969/j.issn.10007369.2020.05.011]
[3]张燕洁,李晓玲,张莹雪,等.健脾活血利水法治疗肝硬化腹水Meta分析[J].陕西中医,2023,(6):801.[doi:DOI:10.3969/j.issn.1000-7369.2023.06.027]
　ZHANG Yanjie,LI Xiaoling,ZHANG Yingxue,et al.A Meta-analysis of the basic treatment of Jianpi Huoxue Lishui method in the treatment of ascites in cirrhosis[J].,2023,(10):801.[doi:DOI:10.3969/j.issn.1000-7369.2023.06.027]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(81960910); 广西名中医戴铭传承工作室建设项目(2022004-005-009)
更新日期/Last Update: 2023-10-09